• Arvinas (NASDAQ:ARVN) announced that the company and its partner, Pfizer (NYSE:PFE), decided to postpone the projected completion date for their jointly conducted Phase 3 trial for the breast cancer therapy vepdegestrant.
• Accordingly, the VERITAC-2 monotherapy clinical trial, designed to test the protein degrader in patients with metastatic breast cancer, is expected to be completed in January, a delayed timeline from the companies’ previous projection for November 2024.
• The duo has made the decision based on the current trial status, including data on enrollments and blinded event rates. Given the revised completion date, Pfizer (NYSE:PFE) and Arvinas (NASDAQ:ARVN) expect to share topline data from VERITAC-2 in Q1 2025.
• With its Q3 2024 results, New Haven, Connecticut-based Arvinas (ARVN) said VERITAC-2, which has completed enrollments in Q4, is anticipated to generate topline data this year or Q1 2025.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。